On June 20, the 2025 PDI Pharmaceutical R&D & Innovation Conference and China Pharmaceutical R&D Top 100 Rankings Release Ceremony, jointly organized by Yaozh.com, China News Service International Communication Group, and China Pharmaceuticals magazine, was held in Chongqing. The event unveiled the 2025 China Pharmaceutical R&D Strength Rankings, where Qidu Pharma earned dual honors: 76th on the 2025 China Comprehensive Pharmaceutical R&D Strength Ranking and 43rd on the 2025 China Chemical Drug R&D Strength Ranking.

As a key player in China’s pharmaceutical R&D sector, Qidu Pharma has consistently adhered to an innovation-driven development strategy, pursuing a dual-path approach of industry-academia collaboration and independent research. The company has established long-term partnerships with prestigious institutions such as Peking University, Shandong University, Tianjin University, and East China University of Science and Technology, achieving breakthroughs in "bottleneck" technologies, filling domestic gaps, and replacing imported products. Leveraging platforms like the National Enterprise Technology Center and Postdoctoral Research Station, Qidu continues to enhance its independent R&D capabilities.

Guided by clinical needs, the company focuses on ten therapeutic areas, actively advancing the development of innovative drugs with proprietary intellectual property rights and conducting consistency evaluations for generic drugs. These efforts accelerate product upgrades and strengthen core competitiveness. In 2024, Qidu secured approvals for 8 specifications of 7 generic drugs, including Inite® (Ibrutinib Capsules), Osuwei® (Omeprazole Sodium Bicarbonate Dry Suspension (I)), and Malinda® (Morpholinonitroazole Sodium Chloride Injection). The company filed 50 patent applications, with 34 granted, including 21 invention patents. To date, 49 specifications of 35 products have passed or are deemed to have passed consistency evaluations. This recognition on two Top 100 lists underscores the industry’s authoritative endorsement of Qidu’s technological innovation prowess.

Moving forward, Qidu Pharma will intensify R&D investments, optimize resource allocation, accelerate system development, and advance global R&D initiatives, further elevating its high-level independent innovation capabilities.